RECENT NEWS

New research by the Medicines and Healthcare products Regulatory Agency (MHRA) in partnership with the GSK Vaccines Institute for Global Health, has moved a vaccine against the highly contagious group A Streptococcus bacterium (Strep A) a step closer to reality.

A £4 million UK research collaboration is set to accelerate the development of affordable, adaptable RNA vaccines to protect animal health, strengthen food security and enhance the UK's preparedness for future disease outbreaks.

The Royal Marsden has opened a pioneering cancer genomics centre in Sutton, designed to help more patients across the UK benefit from personalised cancer treatments and clinical trials.

US-based Real Diagnostics, a clinical laboratory specialising in high-complexity molecular infectious disease and toxicology testing, has announced the acquisition of SimplyTest, a leading provider of saliva-based diagnostic tests for oral health.

Abbott has announced the commercial availability of its next-generation Oncodetect molecular residual disease (MRD) test, a personalised, tumour-informed, whole-genome sequencing test designed to provide molecular insights during and after cancer treatment.

Using the online Dynamic Purchasing System (DPS), NHS Trusts across England and Wales can now source and bring into clinical use the iFAST ONE ultra-rapid AST technology direct from iFAST Diagnostics.

Genomic research and diagnostic firm OGT has announced the launch of the SureSeq myPanel Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukaemia (AML).

Roche has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of over 100 high-medical-value assays.

Diagnostic firm Hologic and laboratory automation company Inpeco have announced the signing of a co-marketing partnership for Inpeco’s automation solution FlexLab X and Hologic’s Panther System in Europe.

The UK Government has confirmed it will continue to accept CE marked medical devices on a long-term basis.

AmplexDiagnostics and Scope Biosciences have collaborated to produce a groundbreaking solution in molecular diagnostics. ‘eazySNP’ combines molecular technologies LAMP and CRISPR to enable the rapid and highly specific detection of genetic variants.

The World Health Organization (WHO) has launched a new five-year strategy for its Hub for Pandemic and Epidemic Intelligence, charting a path towards a world where every country can detect and understand emerging health threats within 24 hours of their appearance by 2030.

PAMEC (Preparing for and mitigating the impacts of environmental change on Diptera-borne disease in the UK) is a new four-year programme funded with £3.75m by UK Research and Innovation (UKRI) as part of a £20m interdisciplinary research fund to tackle epidemic threats.

Researchers from The Pirbright Institute have developed new tools to identify and study a critical group of immune cells in pigs that help generate protective antibodies following vaccination and infection.

Evident has expanded its Pramana digital pathology portfolio with the POD whole-slide imaging (WSI) scanner, a new benchtop system designed to help laboratories produce trusted images.

Medical logistics firm Apian has announced plans to develop a foundation world model for pathology laboratory logistics and automation, collaborating with service provider Synnovis, and incorporating advanced robotics and physical AI.

The next one-day conference hosted by POCT Innovators – Power to Disrupt: Clinical Diagnostics Now, which will take place on Monday 16 November, in Oxford – has unveiled its speaker line up.

Beckman Coulter Diagnostics, part of the Danaher group of companies, has announced the appointment of Catherine ‘Cat’ Jennings as President.

The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations of the UK, in its 2030 Strategy document.

Agilent Technologies has entered into a definitive agreement to acquire digital pathology firm Proscia in an all-cash transaction valued at $240 million in cash and up to an additional $30 million based on achieving future performance milestones.